RSV Infection Clinical Trial
Official title:
Epidemiological and Clinical Characteristics of Hospitalized Patients Under 5 Years Old With RSV Infection in Central China, Wuhan
Verified date | April 2024 |
Source | Tongji Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The study will be a multicenter, hospital-based retrospective study. We plan to collect the clinical and laboratory data among all hospitalized ARTI cases in three hospitals in Wuhan from June 1, 2020 to May 31, 2023 and then analyze the epidemiological and clinical characteristics of RSV infection, clarify the gene types of epidemics under 5 years old children after the outbreak in Wuhan, China.
Status | Enrolling by invitation |
Enrollment | 10000 |
Est. completion date | June 1, 2025 |
Est. primary completion date | December 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 1 Day to 5 Years |
Eligibility | Inclusion Criteria: ?Admission age <5 years old ?Clinical diagnosis of acute respiratory tract infections Exclusion Criteria: Hospital acquired ARTI |
Country | Name | City | State |
---|---|---|---|
China | department of pediatrics, Tongji hospital, Tongji medical college, Huazhong University of Science and Technology | Wuhan | Hubei |
Lead Sponsor | Collaborator |
---|---|
Tongji Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | number of patients with fever | number of patients with fever | at admission | |
Primary | number of patients with cough | number of patients with cough | at admission | |
Primary | number of patients with shortness of breath | number of patients with shortness of breath | at admission | |
Primary | number of patients with shortness of wheeze | number of patients with shortness of wheeze | at admission | |
Primary | number of patients with shortness of vomit | number of patients with shortness of vomit | at admission | |
Primary | number of patients with shortness of rale | number of patients with shortness of rale | at admission | |
Primary | number of patients with shortness of stridor | number of patients with shortness of stridor | at admission | |
Primary | age | age | at admission | |
Primary | gender | female/male | at admission | |
Primary | number of patients with underlying disease | underlying disease include immune deficiency, CHD, BPD, BO, bronchiectasis and asthma and so on | at admission | |
Primary | Imaging examination results | X-Ray/CT | through study completion, an average of 1 year | |
Primary | length of hospital stay length of stay length of stay | length of hospital stay | through study completion, an average of 1 year | |
Primary | number of patients with treatment of antibiotic | number of patients with treatment of antibiotic | through study completion, an average of 1 year | |
Primary | number of patients with treatment of immunoglobulin | number of patients with treatment of immunoglobulin | through study completion, an average of 1 year | |
Primary | number of patients with treatment of glucocorticoids | number of patients with treatment of glucocorticoids | through study completion, an average of 1 year | |
Primary | number of patients with treatment of oxygen inhalation | number of patients with treatment of oxygen inhalation | through study completion, an average of 1 year | |
Primary | number of patients with treatment of ventilation | number of patients with treatment of ventilation | through study completion, an average of 1 year | |
Primary | direct medical cost | direct medical cost | through study completion, an average of 1 year | |
Primary | proportion of different virus genotype | virus genotype include A, B and C | through study completion, an average of 1 year | |
Primary | F protein gene sequence | F protein gene sequence | through study completion, an average of 1 year | |
Primary | number of patients infected with bacteria | number of patients infected with bacteria | through study completion, an average of 1 year | |
Primary | number of patients infected with virus | number of patients infected with virus | through study completion, an average of 1 year | |
Primary | number of patients infected with fungus | number of patients infected with fungus | through study completion, an average of 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03698084 -
RESCEU: Defining the Burden of RSV Disease
|
||
Recruiting |
NCT05550545 -
Infant RSV Infections and Health-related Quality of Life of Families
|
||
Completed |
NCT05587478 -
A Study of EDP-323 in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT06180993 -
Evaluation of the Effectiveness and Impact of Nirsevimab Administered as Routine Immunization
|
||
Suspended |
NCT03909867 -
Emission Patterns of Respiratory Syncytial Virus
|
||
Recruiting |
NCT06259487 -
Coordinated Vaccination Against RSV and Influenza in Patients With Chronic Heart Failure and Its Impact on Prognosis.
|
N/A | |
Not yet recruiting |
NCT04144816 -
Predictors of Respiratory Syncytial Virus (RSV) Hospitalizations in Infants
|
||
Completed |
NCT01090557 -
Exhaled Nitric Oxide in Respiratory Syncytial Virus (RSV) Bronchiolitis: a Pilot Study
|
N/A | |
Terminated |
NCT01475305 -
Intranasal Challenge of Healthy Adults With Respiratory Syncytial Virus (RSV)
|
Phase 1 | |
Not yet recruiting |
NCT05928507 -
FINDER® Instrument and FINDER® FLU A/B, RSV, SARS-CoV-2 Test Clinical Evaluation Protocol
|
||
Completed |
NCT03062917 -
Nasal and Bronchial Absorption Sampling in RSV Bronchiolitis
|
N/A | |
Completed |
NCT03691623 -
A Phase 2a Study to Evaluate EDP-938 in the Virus Challenge Model
|
Phase 2 | |
Completed |
NCT03387137 -
Evaluating the Infectivity, Safety, and Immunogenicity of a Respiratory Syncytial Virus Vaccine (RSV 6120/∆NS2/1030s) in RSV-Seropositive Children and RSV-Seronegative Infants and Children
|
Phase 1 | |
Completed |
NCT05070975 -
Severity of RSV Infections in Twins
|
||
Active, not recruiting |
NCT04938830 -
Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007)
|
Phase 3 | |
Recruiting |
NCT05568706 -
A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.
|
Phase 2 | |
Completed |
NCT03755778 -
Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01483911 -
ALX-0171 Phase I Study, Evaluating Single Ascending Dose and Multiple Dose in Healthy Male Volunteers
|
Phase 1 | |
Recruiting |
NCT06170242 -
A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge Model
|
Phase 2 | |
Completed |
NCT03750383 -
Drug-Drug Interaction Study Between EDP-938, Cyclosporine and Prednisone in Healthy Adult Subjects
|
Phase 1 |